Compugen

Company Overview

Snapshot

Founded in February 1993, Compugen operates with 51–200 employees and has raised a total of $141.92 million across 7 funding rounds from 3 investors. The company went public on NASDAQ in August 2000 and on TASE in January 2002, demonstrating its long-standing presence in the public markets.

Business overview

Compugen is a clinical-stage drug-discovery and development company focused on advancing a therapeutic pipeline primarily in immuno-oncology. The company utilizes a predictive-discovery infrastructure to identify novel drug targets, particularly immune checkpoint candidates, aimed at harnessing the immune system to combat cancer. Compugen's pipeline includes multiple therapeutic opportunities designed to address unmet medical needs in oncology, serving the pharmaceuticals and healthcare sectors.

Strategic signal

In October 2023, Compugen expanded its intellectual property with a new Japanese patent for the triple combination of any anti-PVRIG, TIGIT, and PD-1 antibody for cancer treatment. This development signals the company's continued innovation in immuno-oncology and its strategic efforts to strengthen its patent portfolio, which is crucial for protecting its therapeutic candidates and enhancing its market position in the competitive drug discovery landscape.

Company Intelligence Q&A

What was a significant intellectual property development for Compugen in 2023?

In October 2023, Compugen expanded its intellectual property with a new Japanese patent for the triple combination of any anti-PVRIG, TIGIT, and PD-1 antibody for the treatment of cancer.

When did Compugen report its third-quarter 2023 results?

Compugen reported its third-quarter 2023 results on November 7, 2023.

What clinical data did Compugen present at SITC 2023?

In November 2023, Compugen presented new data at SITC 2023 suggesting the leading edge of its anti-IL18 Binding Protein Antibody, COM503, in treating cancer.

What was a key finding regarding Compugen's COM701 in November 2023?

In November 2023, Compugen announced that its COM701 (anti-PVRIG) mediates anti-tumor activity in patients typically not responding to immunotherapy.

When did Compugen present new clinical and pre-clinical data at SITC 2023?

Compugen presented new clinical and pre-clinical data in multiple presentations at SITC 2023 in September 2023.